Äèñêóññèîííûé Êëóá
  #1  
Ñòàðûé 05.08.2018, 10:42
medstep medstep âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 02.05.2009
Ãîðîä: Êèøèíåâ
Ñîîáùåíèé: 29
Ñêàçàë(à) ñïàñèáî: 26
medstep *
Ïàöèåíòêà 26 ëåò, íåôðîêàëüöèíîç, íèçêèé ÏÒÃ

Êîëëåãè, ïðîøó ïîìîùè â äèàãíîñòèêå ïàöèåíòêè!

26 ëåò. Ðîñò 167 ñì, âåñ 60 êã. ÀÄ 110/80 ìì ðò ñò. ×ÑÑ 80/ìèí.
Ì.ö. ðåãóëÿðíûé, 4 ãîäà íàçàä íîðìàëüíàÿ áåðåìåííîñòü è ðîäû.
Æàëîáû: ëåãêàÿ äðîæü ðóê, ñïàçìû ìûøö êèñòåé, îíåìåíèå íèæíèõ êîíå÷íîñòåé (æàëîáû íå î÷åíü âûðàæåííûå, ïðèñóòñòâóþò íåñêîëüêî ëåò).
6 ìåñÿöåâ íàçàä ïðè ïðîôèëàêòè÷åñêîì îñìîòðå íà ÓÇÈ îáíàðóæåí íåôðîêàëüöèíîç ìîçãîâîãî âåùåñòâà ïî÷åê (çàòåì ïîäòâåðæäåí íà ÊÒ).
Äðóãèå âíóòðåííèå îðãàíû íà ÊÒ è ÓÇÈ áåç îñîáåííîñòåé.
ÄÅÊÑÀ - ïðåäïëå÷üå T-score -1,8, ïîçâîíî÷íèê T-score -1,1, áåäðî T-score -0,5.
02/2018. ÎÀÊ íîðìà, êàëüöèé îáùèé 2,1 (2,15-2,5), ÏÒà 5,6 (15-65), ÒÒà 2,9, ñâÒ4 17 (10-22), ñûâ. æåëåçî 11 (6-25), êðåàòèíèí 88, êàëüöèé â ñóò. ìî÷å 4,025 (2,5-7,5).
05/2018. êàëüöèé îáùèé 2,04 (2,17-2,54), êàëüöèé èîí. 1,17 (1,13-1,31), ÏÒÃ 11,2 (8-51), ôîñôîð 1,27 (0,8-1,4), êðåàòèíèí 68, 25-ÎÍ-Âèò Ä 42 (30-50).
Äèóðåç 2,5 ë. Êðåàòèíèí â ñóòî÷íîé ìî÷å 12667 (97-177).
06/2018. êàëüöèé îáùèé 2,33 (2,17-2,54), êàëüöèé èîí. 1,22 (1,13-1,31), íàòðèé 140 (136-146), Ê 3,77 (3,5-5,0), ôîñôîð 1,37 (0,81-1,45).
07/2018. êàëüöèé îáùèé 2,18 (2,15-2,55), êàëüöèé èîí. 0,93 (0,95-1,2), îáùèé áåëîê 73,6 (66-87), ÏÒÃ 16 (15-65), íàòðèé 139 (136-145), êàëèé 4,57 (3,3-5,1).
Íà ïðîòÿæåíèè 6 ìåñÿöåâ íàáëþäåíèÿ ïàöèåíòêà ìåäèêàìåíòîçíîãî ëå÷åíèÿ íå ïîëó÷àëà.
Âîïðîñû.
1) Åñòü îñíîâàíèÿ ïîäîçðåâàòü ó ïàöèåíòêè ãèïîïàðàòèðåîç (íèçêèé ÏÒÃ + íèçêèé êàëüöèé)?
2) Êàê äàëüøå âåñòè ïàöèåíòêó (äèàãíîñòèêà/ëå÷åíèå)?
Çàðàíåå áëàãîäàðþ çà îòâåòû.
Ìèíèàòþðû
Íàæìèòå íà èçîáðàæåíèå äëÿ óâåëè÷åíèÿ
Íàçâàíèå: íåôðîêàëüöèíîç.jpg
Ïðîñìîòðîâ: 22
Ðàçìåð:	326.8 Êá
ID:	163888  
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 05.08.2018, 14:14
Samitin Samitin âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 27.08.2009
Ãîðîä: Ñàðàòîâ
Ñîîáùåíèé: 2,224
Ñêàçàë(à) ñïàñèáî: 8
Ïîáëàãîäàðèëè 765 ðàç(à) çà 691 ñîîáùåíèé
Samitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ìàãíèé íå èçâåñòåí?
À ïîäîçðåâàòü - îò÷åãî áû è íåò, îñíîâàíèé - âî âñå ïîëÿ...

Íàñêîëüêî ÿ ñìîã ïðîäðàòüñÿ ñêâîçü îòñóòñòâóþùèå åäèíèöû èçìåðåíèÿ, ñóòî÷íàÿ ýêñêðåöèÿ êàëüöèÿ ðàâíà ~470 ìã (æåëàòåëüíî <300), êàëüöèé-ôîñôàòíîå ïðîèçâåäåíèå (ïðàâäà, ñ íåêîððåêòèðîâàííûì êàëüöèåì) - ïðèìåðíî 36 (ä.á. ìåíåå 55).

Êàëüöèòðèîë è êàëüöèé?

Òóðåöêèå òîâàðèùè [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ñëó÷àé îïèñûâàëè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 05.08.2018, 16:19
camelot camelot âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 28.08.2010
Ãîðîä: ×åëÿáèíñê
Ñîîáùåíèé: 1,628
Ñêàçàë(à) ñïàñèáî: 171
Ïîáëàãîäàðèëè 477 ðàç(à) çà 471 ñîîáùåíèé
camelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Êðîìå òîãî, ïðè÷èí äëÿ íåôðîêàëüöèíîçà ïîëíî íå ýíäîêðèíîëîãè÷åñêèõ. Êàê ïàöèåíòêà ê Âàì ïîïàëà? Åå ïåðâîíà÷àëüíûå æàëîáû? Âàø ñëó÷àé-êàê ðàç "ãèïåðêàëüöèóðèÿ áåç ãèïåðêàëüöèåìèè".
Öèòàòà:
Hypercalciuria without hypercalcemia — The following conditions can cause nephrocalcinosis in association with hypercalciuria without hypercalcemia:

●Distal renal tubular acidosis

●Medullary sponge kidney

●Neonatal nephrocalcinosis and loop diuretics

●Inherited tubulopathies

●Chronic hypokalemia

●Beta thalassemia
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 06.08.2018, 20:47
medstep medstep âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 02.05.2009
Ãîðîä: Êèøèíåâ
Ñîîáùåíèé: 29
Ñêàçàë(à) ñïàñèáî: 26
medstep *
Êîëëåãè, ñïàñèáî çà îòâåòû!

Ïàöèåíòêà áûëà íàïðàâëåíà êî ìíå îò óðîëîãà, æàëîá ïðè îáíàðóæåíèè íåôðîêàëüöèíîçà íå ïðåäúÿâëÿëà. Óðîëîã íàçíà÷èë äèåòó ñ îãðàíè÷åíèåì êàëüöèÿ.
Ìàãíèé èçâåñòåí. Èññëåäîâàëñÿ 2 ðàçà, Mg 0,77 mmol/l (0,62-0,94), Mg 0,84 (0,66-1,07).
Êàê ïîíèìàþ (ïåðåøåë ïî ññûëêå âûøå), ó òóðåöêèõ òîâàðèùåé íåôîêàëüöèíîç áûë ïîáî÷íûì ýôôåêòîì îò ëå÷åíèÿ, à íå âïåðâûå âûÿâëåííûé íåôðîêàëüöèíîç, êàê â ýòîì ñëó÷àå.
Ä-ð Ñàìèòèí, Âû ïðåäëàãàåòå â ýòîé ñèòóàöèè íàçíà÷èòü ïàöèåíòêå êàëüöèòðèîë è êàëüöèé?
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 06.08.2018, 23:46
Samitin Samitin âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 27.08.2009
Ãîðîä: Ñàðàòîâ
Ñîîáùåíèé: 2,224
Ñêàçàë(à) ñïàñèáî: 8
Ïîáëàãîäàðèëè 765 ðàç(à) çà 691 ñîîáùåíèé
Samitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïîêà íå ïðåäëàãàþ, ïðîñòî ïûòàþñü âñëóõ äóìàòü. Âû ïðàâû â òîì, ÷òî ÷àùå âñåãî íåôðîêàëüöèíîç íà ôîíå ãèïîïàðàòèðåîçà ðàññìàòðèâàåòñÿ êàê îñëîæíåíèå òåðàïèè êàëüöèåì è âûñîêèìè äîçàìè âèòàìèíà D (õîòÿ êàëüöèôèêàöèÿ áàçàëüíûõ ãàíãëèåâ, êàæåòñÿ, áûëà îïèñàíà è âíå òåðàïèè).  äàííîì ñëó÷àå êàê-òî íå î÷åíü ïîäõîäèò.

Ñ äðóãîé ñòîðîíû, áûâàåò òàêàÿ âåùü, êàê îáóñëîâëåííàÿ (â ò.÷. ñïîðàäè÷åñêîé) ñòèìóëèðóþùåé ìóòàöèåé â ãåíå CaSR àóòîñîìíî-äîìèíàíòíàÿ ãèïîêàëüöåìèÿ, êîòîðàÿ áèîõèìè÷åñêè âïîëíå ñõîäèò çà ïåðâè÷íûé èäèîïàòè÷åñêèé ãèïîïàðàòèðåîç, ÷àñòåíüêî ÿâëÿåòñÿ áåññèìòîìíîé/ìàëîñèìïòîìíîé è âûÿâëÿåòñÿ âî âçðîñëîì ñîñòîÿíèè ïðè ñëó÷àéíîì (â òåõ ñòåïÿõ, ãäå ýòî - ðóòèíà) îïðåäåëåíèè êàëüöèÿ. Äà¸ò êàê ðàç ãèïåðêàëüöèóðèþ áåç ãèïåðêàëüöåìèè.  òàêîì ñëó÷àå ñ êàëüöèåì è D íóæíî áûòü êðàéöíå îñòîðîæíûì, ò.ê. ãèïåðêàëüöèóðèÿ è êàëüöèíîç ìîãóò óñóãóáèòüñÿ. Òèàçèäíûå äèóðåòèêè, âðîäå áû, ìîãóò áûòü èñïîëüçîâàíû (ñíèæàþò ýêñêðåöèþ êàëüöèÿ, ñîîòâåòñòâåííî, ïîâûøàÿ êàëüöåìèþ). À áåññèìïòîìíûõ ïàöèåíòîâ ìîæíî è íå ëå÷èòü.

Îïèñàí è ïåðâè÷íûé ãèïîïàðà, ñî÷åòàþùèéñÿ â ðàìêàõ ïîëèãëàíäóëÿðíîãî ñèíäðîìà ñ ïðîäóêöèåé àíòèòåë ê CaSR, îáëàäàþùèõ ñòèìóëèðóþùèì äåéñòâèåì.
Äà è ìóòàöèè CaSR ïðè ïåðâè÷íîì ãèïîïàðà áûëè îïèñàíû... È òîæå - ãèïåðêàëüöèóðèÿ áåç ãèïåðêàëüöåìèè.

Ñëîæíî. Ïîäîæä¸ì åùå ìíåíèé.
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 08.08.2018, 07:41
Samitin Samitin âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 27.08.2009
Ãîðîä: Ñàðàòîâ
Ñîîáùåíèé: 2,224
Ñêàçàë(à) ñïàñèáî: 8
Ïîáëàãîäàðèëè 765 ðàç(à) çà 691 ñîîáùåíèé
Samitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñ òðåòüåé ñòîðîíû, çà÷åì ëîìàòü ãîëîâó - ãåíåòè÷åñêîå èññëåäîâàíèå ïðè èçîëèðîâàííîì ãèïîïàðàòèðåîçå âñ¸ ðàâíî æåëàòåëüíî.
Åñëè îòòàëêèâàòüñÿ îò âûæèìêè èç åâðîïåéñêèõ ðåêîìåíäàöèé (Eur J Endocrinol. 2015; 173(2):G1-20):

Öèòàòà:
  • Consider a diagnosis of chronic hypoparathyroidism (HypoPT) in a patient with hypocalcemia and inappropriately low parathyroid hormone (PTH) levels.
  • Consider genetic testing and/or family screening in a patient with HypoPT of unknown etiology.
  • Treatment targeted to maintain serum calcium level (albumin adjusted total calcium or ionized calcium) in the lower part or slightly below the lower limit of the reference range (target range) is suggested, with patients being free of symptoms or signs of hypocalcemia.
  • Treat patients with chronic HypoPT with symptoms of hypocalcemia and/or an albumin adjusted serum calcium level <2.0 mmol/L (<8.0 mg/dL/ionized serum calcium levels [S-Ca 2] <1.00 mmol/L).
  • Offer treatment to asymptomatic patients with chronic HypoPT and an albumin adjusted calcium level between 2.0 mmol/L (8.0 mg/dL/S-Ca 2+ 1.00 mmol/L) and the lower limit of the reference range in order to assess whether this may improve their well-being.
  • Use activated vitamin D analogues plus calcium supplements in divided doses as the primary therapy.
  • If activated vitamin D analogues are not available, treat with calciferol (preferentially cholecalciferol).
  • Titrate activated vitamin D analogues or cholecalciferol in such a manner that patients are without symptoms of hypocalcemia and serum calcium levels are maintained within the target range.
  • Provide vitamin D supplementations in a daily dose of 400–800 IU to patients treated with activated vitamin D analogues.
  • In a patient with hypercalciuria, consider a reduction in calcium intake, a sodium-restricted diet, and/or treatment with a thiazide diuretic.
  • In a patient with renal stones, evaluate renal stone risk factors and management according to relevant international guidelines.
  • In a patient with hyperphosphatemia and/or an elevated calcium-phosphate product, consider dietary interventions and/or adjustment of treatment with calcium and vitamin D analogues.
  • In a patient with hypomagnesemia, consider measures that may increase serum magnesium levels.
  • The routine use of replacement therapy with PTH or PTH analogues is not recommended.
Ãäå áû åù¸ íàéòè òó ãåíåòèêó â ñâîáîäíîì äîñòóïå. Ïðàâäà, ìîæíî ðîäñòâåííèêîâ ïîîáñëåäîâàòü.
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 08.08.2018, 21:51
medstep medstep âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 02.05.2009
Ãîðîä: Êèøèíåâ
Ñîîáùåíèé: 29
Ñêàçàë(à) ñïàñèáî: 26
medstep *
Ä-ð Ñàìèòèí, áîëüøîå ñïàñèáî çà ó÷àñòèå â ìîåì ñëó÷àå. Î÷åíü ïîìîãàåòå.
Êñòàòè, ó ïàöèåíòêè åñòü íåáîëüøàÿ ïîëîæèòåëüíàÿ äèíàìèêà â ëàáîðàòîðíûõ ïîêàçàòåëÿõ ïîñëå îãðàíè÷åíèÿ â äèåòå êàëüöèÿ è ñîëè (ïî ðåêîìåíäàöèè óðîëîãà). Ïðèìåðíî ñ êîíöà ìàÿ ïàöèåíòêà ïðèäåðæèâàåòñÿ ýòîé äèåòû.
Ñåé÷àñ ó íåå êàê ðàç êàëüöèé áàëàíñèðóåò íà íèæíåé ãðàíèöå íîðìû, ýòî æå öåëü ëå÷åíèÿ ãèïîïàðà. Òî åñòü ïîêà îáîéäåìñÿ áåç êàëüöèòðèîëà, êàëüöèÿ è âèò Ä..?
Èíòåðåñåí ìîìåíò ñ íàçíà÷åíèåì òèàçèäíîãî äèóðåòèêà. Êàêîé ïðåïàðàò îáû÷íî (èç îïûòà) íàçíà÷àåòñÿ è â êàêîé ïåðâîíà÷àëüíîé äîçå?
Ïîëó÷àåòñÿ, ó ìîåé ïàöèåíòêè ãèïîïàðà + ñî÷åòàííàÿ ðåíàëüíàÿ ïàòîëîãèÿ?
Èìååò ëè ñìûñë èñêàòü ãåíåòèêó, ýòî ñìîæåò êàê-òî ïîìî÷ü â òàêòèêå âåäåíèÿ ïàöèåíòêè?
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 09.08.2018, 10:19
Samitin Samitin âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 27.08.2009
Ãîðîä: Ñàðàòîâ
Ñîîáùåíèé: 2,224
Ñêàçàë(à) ñïàñèáî: 8
Ïîáëàãîäàðèëè 765 ðàç(à) çà 691 ñîîáùåíèé
Samitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
 òàêòèêå âåäåíèÿ ãåíåòèêà âðÿä ëè ñèëüíî ïîìîæåò; ýòî áîëüøå äëÿ ïîäòâåðæäåíèÿ ñâîèõ ãåíèàëüíûõ ïðîçðåíèé è äëÿ ðàñ÷¸ñûâàíèÿ ÷óâñòâà ñîáñòâåííîé âàæíîñòè. Íó èëè âäðóã íîâàÿ ìóòàöèÿ ïîïàä¸òñÿ - áóäåò èíòåðåñíî òåì, êòî èõ êîëëåêöèîíèðóåò. Ïîïðîáóéòå ïîèñêàòü â ñåòè - ì.á., êàêèå-íèáóäü öåíòðû â ÅÑ íàõàëÿâó ìîãóò ñäåëàòü.

Êðîìå òîãî, áûâàåò è [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]:

Öèòàòà:
Up to 20% of patients with clinically typical autosomal dominant hypoparathyroidism may also lack demonstrable CASR mutations.
Äðóãîé âîïðîñ, ÷òî õîòåëîñü áû ïîñìîòðåòü êàëüöèé/ÏÒÃ/êàëüöèóðèþ ó ðîäñòâåííèêîâ - îïÿòü æå, ÷òîáû õîòü êàê-òî óáåäèòüñÿ â õàðàêòåðå ïðîöåññà. Ìîæåò áûòü, òàì ïîëñåìüè íóæäàåòñÿ â ãèïîòèàçèäå...

×òî êàñàåòñÿ ñîáñòâåííî ëå÷åáíûõ ìåðîïðèÿòèé, ñóòü ïðèáëèçèòåëüíî òàêîâà ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]):

Öèòàòà:
PTH is low or even undetectable in patients with activating CASR mutations. This leads to impaired PTH-dependent renal 1-alpha-hydroxylation of 25-OH-vitamin D3 and thus to reduced formation of 1,25-dihydroxyvitamin D3. We therefore prefer the use of either calcitriol or alfacalcidol. Raising serum calcium by vitamin D3 and calcium supplementation inevitably aggravates hypercalciuria in patients with activating CASR mutations (97, 98, 100, 102). There is considerablå phenotypic variation (95, 98) and tissue calcifications were similar in ADH patients with and without hypercalciuria (100) or in patients with or without vitamin D and calcium therapy in a large kindred (98).
There is, however, general consensus, that therapy with vitamin D and calcium should be given cautiously and only in the amount necessary to reduce symptoms to an acceptable level and to prevent severe complications such as seizures and cardiac arrhythmias.
Öèòàòà:
Treatment with hydrochlorothiazide (HCT) has been reported to reduce urinary calcium excretion in patients with ADH (106) and BS type 5 (29, 96, 103). The doses given ranged from 0.5 mg/kg/day in young adults (96) to 5 mg/kg/day in infants (106). HCT treatment, however, is not always successful (95). Its effectiveness seems to decline over time (29) and common side effects like hypokalemia limit its use (29). In patients, where hypercalciuria is an issue, HCT is worth a trial.
 ÀïÒóÄåéòå îáðàçöà 2013 ãîäà åñòü ñëîâà î òîì, ÷òî ãèïîòèàçèä â äîçå 25-100 ìã/ñóò íàçíà÷åòñÿ ïðè ïðèáëèæåíèè ýêñêðåöèè êàëüöèÿ ê 250 ìã/ñóò (ó ïàöèåíòêè ÿ âî âòîðîì ïîñòå íàñ÷èòàë, êàæåòñÿ, 470).

Ïîýòîìó ãèïîòèàçèä âûãëÿäèò ëîãè÷íûì øàãîì ïåðâîé î÷åðåäè, äîçà, âåðîÿòíî, îïðåäåëÿåòñÿ àðòåðèàëüíûì äàâëåíèåì, äèóðåòè÷åñêèì ýôôåêòîì è êîíòðîëåì êàëüöèÿ êðîâè è ìî÷è. Êàëüöèòðîèîë â ìèêðîäîçàõ, íàâåðíîå, ìîæíî ïîïûòàòüñÿ ðàññìîòðåòü â êà÷åñòâå ñëåäóþùåãî øàãà ïðè íàëè÷èè ñèìïòîìîâ, íî îá ýòîì ëó÷øå äóìàòü ïî ôàêòó.
 îòíîøåíèè êàëüöèÿ íå âîçüìóñü ñêàçàòü, îòíîñèòñÿ ëè ñëîâî "îãðàíè÷åíèå" ê äîïîëíèòåëüíî ïðèíèìàåìîìó ïðåïàðàòó èëè ê íåîáõîäèìîñòè ñíèæàòü ïèùåâîå ïîñòóïëåíèå. Íàäåþñü âñ¸ æå íà ïåðâûé âàðèàíò.

ÏÒÃ íàì íåäîñòóïåí, õîòÿ ïî òó ñòîðîíó ëóæè èìååòñÿ. Äîëãîæäàííûõ êàëüöèéëèòêîâ ïîêà, êàæåòñÿ, òîæå â âîëíàõ íå âèäíî.

Íàäåþñü, êòî-òî èç áîëåå óìíûõ êîëëåã ñìîæåò âíåñòè áîëüøå ÿñíîñòè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 09.08.2018, 19:38
camelot camelot âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 28.08.2010
Ãîðîä: ×åëÿáèíñê
Ñîîáùåíèé: 1,628
Ñêàçàë(à) ñïàñèáî: 171
Ïîáëàãîäàðèëè 477 ðàç(à) çà 471 ñîîáùåíèé
camelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcamelot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âàñèëèé, ñïàñèáî, çà ñîîáùåíèå î ìóòàöèè CASR. Äëÿ ìåíÿ áûëî íåîæèäàííûì, ÷òî îíà ìîæåò áûòü ïðè íèçêî-íîðìàëüíîì ÏÒÃ è áåññèìïòîìíîé. Âîò òåïåðü ñîêðóøàþñü- íàâåðíîå, ïðîïóñòèëà åå ó ïàöèåíòà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #10  
Ñòàðûé 13.08.2018, 23:10
medstep medstep âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 02.05.2009
Ãîðîä: Êèøèíåâ
Ñîîáùåíèé: 29
Ñêàçàë(à) ñïàñèáî: 26
medstep *
Âàñèëèé, ñïàñèáî çà âíåñåíèå ÿñíîñòè â ýòîò ñëó÷àé! Äâèãàþñü â ñòîðîíó íàçíà÷åíèÿ ãèïîòèàçèäà. Ñ êàëüöèòðèîëîì ïîêà ïîäîæäåì. Ïîïðîáóþ äîáðàòüñÿ äî ðîäñòâåííèêîâ è ïîñìîòðåòü ÏÒÃ/êàëüöèé/êàëüöèóðèþ.
Ïàöèåíòêà íèêîãäà íå ïîëó÷àëà ïðåïàðàòû êàëüöèÿ èëè Âèò Ä. Óðîëîã îãðàíè÷èë ïèùåâîå ïîñòóïëåíèå êàëüöèÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò


Îïöèè òåìû Ïîèñê â ýòîé òåìå
Ïîèñê â ýòîé òåìå:

Ðàñøèðåííûé ïîèñê
Îïöèè ïðîñìîòðà

Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 09:34.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.